The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
January 8th 2025
An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.
Ray Comenzo, MD, Discusses ANDROMEDA Trial in AL Amyloidosis Patients
Ray Comenzo, MD, highlights promising ANDROMEDA phase 3 trial, which evaluated the efficacy of subcutaneous daratumumab and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy for newly diagnosed light chain (AL) amyloidosis patients.
Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis Patients
Updated research regarding the ANDROMEDA study indicates the efficacy of subcutaneous daratumumab (DARA SC) and cyclophosphamide, bortezomib, and dexamethasone (CyBorD) as a combination therapy in newly diagnosed light chain (AL) amyloidosis patients.
MDNN: Cinnamon-Flavored E-Cigarettes, Hypertension Prevalence, Right-to-Try Law
May 25th 2018This week on MDNN: Cinnamon flavoring in e-cigarettes has been found to disrupt the lungs’ anti-bacterial defense system, new hypertension guidelines have increased the condition's prevalence, and the US Congress passed a right-to-try bill.